[go: up one dir, main page]

MX2019000829A - Analogos de insulina. - Google Patents

Analogos de insulina.

Info

Publication number
MX2019000829A
MX2019000829A MX2019000829A MX2019000829A MX2019000829A MX 2019000829 A MX2019000829 A MX 2019000829A MX 2019000829 A MX2019000829 A MX 2019000829A MX 2019000829 A MX2019000829 A MX 2019000829A MX 2019000829 A MX2019000829 A MX 2019000829A
Authority
MX
Mexico
Prior art keywords
insulin
present
insulin analogs
relates
analogs
Prior art date
Application number
MX2019000829A
Other languages
English (en)
Inventor
Gerbrandt Tasman Menting John
Smith Brian
Hung- Chieh CHOU Danny
Safavi-Hemami Helena
Colin Lawrence Michael
M Baldomero Olivera
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Priority claimed from PCT/AU2017/050758 external-priority patent/WO2018014091A1/en
Publication of MX2019000829A publication Critical patent/MX2019000829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)

Abstract

La presente invención se refiere particularmente a análogos de insulina que tienen cadenas B cortas. La presente invención también se refiere a la estructura cristal de insulina del veneno de caracoles cono y a métodos para utilizar el cristal, así como información estructural relacionada para cribar y diseñar análogos de insulina que interactúen o modelen el receptor de insulina. La presente invención también se refiere a métodos terapéuticos y profilácticos utilizando análogos de insulina.
MX2019000829A 2016-07-22 2017-07-21 Analogos de insulina. MX2019000829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
US201762483118P 2017-04-07 2017-04-07
PCT/AU2017/050758 WO2018014091A1 (en) 2016-07-22 2017-07-21 Insulin analogs

Publications (1)

Publication Number Publication Date
MX2019000829A true MX2019000829A (es) 2019-08-29

Family

ID=65524551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000829A MX2019000829A (es) 2016-07-22 2017-07-21 Analogos de insulina.

Country Status (15)

Country Link
US (2) US11248034B2 (es)
EP (1) EP3487876A4 (es)
JP (2) JP7143275B2 (es)
KR (2) KR102529353B1 (es)
CN (2) CN110072884B (es)
AU (1) AU2021269301B2 (es)
BR (1) BR112019000991A2 (es)
CL (1) CL2019000159A1 (es)
CR (1) CR20190096A (es)
IL (1) IL264330B2 (es)
MA (1) MA45727A (es)
MX (1) MX2019000829A (es)
RU (1) RU2769476C2 (es)
SG (1) SG11201900181RA (es)
ZA (1) ZA201901095B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487876A4 (en) 2016-07-22 2020-02-19 University of Utah Research Foundation INSULIN ANALOGS
EP3506945A4 (en) * 2016-08-30 2020-07-15 Board of Regents, The University of Texas System PRODUCTION OF SELENO-BIOLOGICALS IN GENETICALLY RECODED ORGANISMS
WO2023229624A1 (en) * 2022-05-26 2023-11-30 Transdermal Delivery Solutions Corp. (D.B.A. Hypospray Pharma) Transdermal insulin formulations and methods of use thereof
US20250158116A1 (en) 2022-05-31 2025-05-15 Lg Energy Solution, Ltd. Polymer solid electrolyte and manufacturing method therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104305C1 (ru) * 1986-08-29 1998-02-10 Ново Нордиск А.С. Аналоги инсулина человека, способ их получения, раствор для инъекций
WO2005095443A1 (ja) * 2004-03-31 2005-10-13 Cardio Incorporated ペプチド改変を利用したドラッグデリバリーシステム
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
EP2178909B1 (en) * 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
US9200053B2 (en) * 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
BRPI0916560A2 (pt) 2008-07-31 2015-11-10 Univ Case Western Reserve análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
CN102245633A (zh) * 2008-12-09 2011-11-16 诺沃—诺迪斯克有限公司 新的胰岛素类似物
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
CN103889443A (zh) * 2011-06-17 2014-06-25 哈洛齐梅公司 使用透明质酸降解酶的持续皮下胰岛素输注法
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
KR20150138251A (ko) * 2013-03-15 2015-12-09 케이스 웨스턴 리저브 유니버시티 부위 2 인슐린 유사체
KR20160019547A (ko) * 2013-06-14 2016-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 안정화된 폴리펩티드 인슐린 수용체 조절제
AU2017298565B2 (en) 2016-07-22 2021-08-19 The Walter And Eliza Hall Institute Of Medical Research Insulin analogs
EP3487876A4 (en) 2016-07-22 2020-02-19 University of Utah Research Foundation INSULIN ANALOGS
EP4048686A4 (en) * 2019-10-24 2024-01-03 University Of Utah Research Foundation Novel mini-insulin with extended c-terminal a chain

Also Published As

Publication number Publication date
JP2019534843A (ja) 2019-12-05
KR102529353B1 (ko) 2023-05-04
SG11201900181RA (en) 2019-02-27
CN110072884A (zh) 2019-07-30
RU2769476C2 (ru) 2022-04-01
EP3487876A4 (en) 2020-02-19
KR20190039719A (ko) 2019-04-15
NZ750355A (en) 2023-10-27
EP3487876A1 (en) 2019-05-29
CL2019000159A1 (es) 2019-08-16
CN110072884B (zh) 2023-07-28
IL264330B2 (en) 2024-05-01
JP7143275B2 (ja) 2022-09-28
CR20190096A (es) 2019-09-16
RU2019100497A3 (es) 2021-05-11
IL264330B1 (en) 2024-01-01
JP2022191233A (ja) 2022-12-27
RU2019100497A (ru) 2020-08-24
US20220340636A1 (en) 2022-10-27
AU2021269301A1 (en) 2021-12-09
AU2021269301B2 (en) 2023-12-21
BR112019000991A2 (pt) 2019-07-02
ZA201901095B (en) 2022-04-28
IL264330A (es) 2019-03-31
US12410228B2 (en) 2025-09-09
US20190241640A1 (en) 2019-08-08
US11248034B2 (en) 2022-02-15
CN116874584A (zh) 2023-10-13
MA45727A (fr) 2019-05-29
KR20230070049A (ko) 2023-05-19

Similar Documents

Publication Publication Date Title
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2016004461A (es) Analogos de glucagon acilados.
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
CL2016000908A1 (es) Métodos para el tratamiento de afecciones asociados a la activación del complemento dependiente de masp-2 declaración relacionada con el listado de secuencias
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
EA201691911A1 (ru) Быстродействующие композиции инсулина
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
GT201300319A (es) Coagonistas del receptor de glucagón / glp-1
MX384292B (es) Metodos utiles en la sintesis de analogos de halicondrina b.
MX2020001835A (es) Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
UY36870A (es) Análogos de insulina novedosos
MX2022013454A (es) Moduladores de la actividad del complemento.
MX2016015630A (es) Nuevos compuestos.
MX378186B (es) Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.
MX378108B (es) Anticuerpos anti-met y composiciones.
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
MX2019000829A (es) Analogos de insulina.
CO2017005404A2 (es) Anticuerpos contra il-6
MX2017006565A (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CR20160448A (es) Nuevos derivados de piridina
CL2020000310A1 (es) Análogos de insulina acilados novedosos y usos de estos.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
DOP2016000064A (es) Derivados de fenilalanina sustituidos